2019

NervGen Pharma Appoints Paul Brennan As President & Chief Executive Officer / Lloyd Mackenzie Appointed to The New Position of Chief Operating Officer

NervGen Pharma Completes Share Issuance to Drug Manufacturing Partner CSBio

NervGen Pharma Receives Investment from Drug Manufacturing Partner / CSBio Invests US$1,500,000 As Part of Manufacturing Contract For Clinical Trial Product

NervGen Pharma Expands Platform Into Alzheimer's Disease / NervGen Pharma’s NVG-291 Compound on Track to Begin Phase 1 in Q1 2020

NervGen Pharma Announces Clinical Development Plan For the Treatment of Nerve Damage and Neurodegenerative Diseases / NervGen Reports Results of Annual General Meeting of Shareholders

NervGen Pharma’s Multiple Sclerosis Development Program Targeting Nerve Remylenation Supported by Publication of Independent Peer Reviewed Paper

NervGen Grants Stock Option Shares for Investor Relations Consulting Services

NervGen Amends Investor Relations Agreement

NervGen Pharma Launches Multiple Sclerosis Program Targeting Nerve Remyelination / Lead Indication for Spinal Cord Injury Continues to Advance to Phase One Clinical Trial